PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.
PFA has emerged as the preferred ablation strategy for many electrophysiologists, but some questions do remain about its long-term impact. HRS is developing this new registry to be as user-friendly for clinicians as possible.
The American College of Cardiology and American Heart Association have issued new guidelines for the management of congenital heart disease in adults. The document outlines how to manage these patients, the challenges they face and much more.
PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations.
Although these tools have proven themselves valuable in numerous settings, they must be used with caution, especially by patients and nonradiologist providers who may be seeking clarification on imaging reports.
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.
![An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.](/sites/default/files/styles/240x220/public/2024-04/screen_shot_2024-04-26_at_10.55.10_am.png.webp?itok=ZMT_brpB)
